Alnylam Pharmaceuticals (United States)

Alnylam Pharmaceuticals (United States)

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Publications

All publications